Harrow Q3 Revenue $99.3M but Adjusted EBITDA Guidance Cut to $40M+ from $80-100M
HROW sits 21% above its 52-week low of $25.76 on elevated volume (1.9× avg).
Summary
Harrow posted record Q3 revenue of $99.3 million and $9.8 million of net income, but cut full-year Adjusted EBITDA guidance to more than $40 million from $80-100 million while reaffirming revenue guidance. The IHEEZO QUELL Phase 4 study also missed its primary endpoint.
Key Events · Earnings and Guidance · HROW
-
Record Q3 Revenue of $99.3M
Revenue rose 39% year over year from $71.6 million, with branded products at $83.5 million, up 62% and about 84% of total. GAAP net income was $9.8 million, including a $5.0 million litigation settlement gain.
-
Adjusted EBITDA Guidance Slashed
Full-year 2026 Adjusted EBITDA guidance was cut to more than $40 million from $80-100 million, including more than $33 million in Q4. Management cited the first-half VEVYE shortfall, lower gross margins, and accelerated G-MELT, R&D and TYRVAYA spending.
-
Revenue Guidance Reaffirmed, Q4 Bar High
Full-year revenue guidance held at $350-365 million, requiring Q4 revenue of about $136-151 million — roughly 37-52% sequential growth versus a 2024-2025 average Q3-to-Q4 step-up of about 30%.
-
IHEEZO QUELL Misses Primary Endpoint
The Phase 4 study did not meet non-inferiority: successful anesthesia in 55.2% of IHEEZO patients versus 59.7% for proparacaine plus subconjunctival lidocaine. Exploratory measures favored IHEEZO on 24-hour pain (2.9 vs 3.7) and adverse events (27% vs 47%).
Analysis · HROW · Life Sciences
The headline is the profit outlook, not the top line. Revenue reached a record $99.3 million, up 39% year over year, and GAAP net income swung to $9.8 million from a $17.3 million loss last quarter. But full-year Adjusted EBITDA guidance was slashed to more than $40 million from $80-100 million, with management citing the first-half VEVYE shortfall, lower gross margins, and pulled-forward spending on the G-MELT NDA, R&D and the TYRVAYA integration. Revenue guidance of $350-365 million was reaffirmed, yet hitting it requires $136-151 million in Q4, roughly 37-52% sequential growth. Separately, the IHEEZO QUELL Phase 4 study missed its primary non-inferiority endpoint, though exploratory pain and tolerability measures favored IHEEZO. The stock now trades against a much lower earnings base than investors were promised.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HROW was trading at $31.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $25.76 to $54.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.